Advertisement

Aflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema

  • Abeer M. Khattab
  • Sherein M. HagrasEmail author
  • AhmedHosni AbdElhamid
  • Magda A. Torky
  • Eman A. Awad
  • Ameera G. Abdelhameed
Retinal Disorders
  • 46 Downloads

Abstract

Purpose

To assess the impact of micropulsed laser (MPL) on modifying the number of aflibercept injections when used as an adjuvant therapy in diabetic macular edema (DME).

Methods

A prospective randomized interventional clinical study included patients with DME attending Al Hadi Clinic, Kuwait, during the period from May 2017 to December 2018. Patients were allocated in two groups; group A received aflibercept injections alone and group B received combined aflibercept injections followed by MPL within a week. The primary outcome was the number of Aflibercept injections in each group guided by the change in central macular thickness (CMT). All the patients were followed for 18 months. Secondary outcome measures included best corrected visual acuity (BCVA), contrast sensitivity (CS), and any recorded complications.

Results

Fifty-four eyes of 51 patients were included (27 in each group). There was no statistically significant difference between the two groups in baseline characteristics except for the age that was statistically higher in group B (p = 0.001). The number of injections were significantly lower in group B (4.1 ± 1.1) than group A (7.3 ± 1.1) (p < 0.005). At 18th month, there was significant reduction in CMT in both groups (p < 0.005) with no statistical difference between the two groups (p = 0.989). Final BCVA in both groups showed statistically significant improvement (p < 0.005) without statistically significant difference between the two groups (p = 0.082). In both groups, the CS showed significant improvement from baseline (p < 0.005). No ocular or systemic adverse effects were observed in either group.

Conclusion

Supplemental MPL in eyes with DME may decrease the burden of the aflibercept injection frequency while resulting in comparable anatomical and visual outcomes.

Keywords

Aflibercept Anti-VEGF Diabetic macular edema Micropulsed laser Subthreshold 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Bhagat N, Grigorian RA, Tutela A et al (2009) Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 54:1–32CrossRefGoogle Scholar
  2. 2.
    Lee CM, Olk RJ (1991) Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 98:1594e1602Google Scholar
  3. 3.
    Barkmeier AJ, Nicholson BP, Akduman L (2009) Effectiveness of laser photocoagulation in clinically significant macular edema with focal versus diffuse parafoveal thickening on optical coherence tomography. Ophthalmic Surg Lasers Imaging 40:472–479CrossRefGoogle Scholar
  4. 4.
    Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 103:1796–1806CrossRefGoogle Scholar
  5. 5.
    Nguyen QD, Shah SM, Khwaja AA et al (2010) Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 117:2146–2151CrossRefGoogle Scholar
  6. 6.
    Massin P, Bandello F, Garweg JG et al (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33:2399–2405CrossRefGoogle Scholar
  7. 7.
    Korobelnik JF, Do DV, Schmidt-Erfurth U et al (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121:2247–2254CrossRefGoogle Scholar
  8. 8.
    Arevalo JF, Sanchez JG, Wu L et al (2009) Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American collaborative retina study group at 24 months. Ophthalmology 116:1488–1497CrossRefGoogle Scholar
  9. 9.
    Au A, Singh RP (2016) A multimodal approach to diabetic macular edema. J Diabetes Complicat 30(3):545–553CrossRefGoogle Scholar
  10. 10.
    Chen G, Li W, Tzekov R, Jiang F, Mao S, Tong Y (2014) Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema: a meta-analysis of randomized controlled trials. PLoS One 9(12):e115797CrossRefGoogle Scholar
  11. 11.
    Berger A, Sheidow T, Cruess AF, Arbour JD, Courseau AS, de Takacsy F (2015) Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME. Can J Ophthalmol 50(3):209–216CrossRefGoogle Scholar
  12. 12.
    Luttrull JK, Sinclair SH (2014) Safety of transfoveal subthreshold diode micropulse laser for fovea-involving diabetic macular edema in eyes with good visual acuity. Retina 34(10):2010–2020CrossRefGoogle Scholar
  13. 13.
    Yu AK, Merrill KD, Truong SN et al (2013) The comparative histologic effects of subthreshold 532- and 810-nm diode micropulse laser on the retina. Invest Ophthalmol Vis Sci 54(3):2216–2224CrossRefGoogle Scholar
  14. 14.
    Thinda S, Patel A, Hunter AA, Moshiri A, Morse LS (2014) Combination therapy with subthreshold diode laser micropulse photocoagulation and intravitreal anti-vascular endothelial growth factor injections for diabetic macular edema. Invest Ophthalmol Vis Sci 55(13):6363Google Scholar
  15. 15.
    Ford JA, Lois N, Royle P, Clar C, Shyangdan D, Waugh N (2013) Current treatments in diabetic macular oedema: systematic review and metaanalysis. BMJ Open 3(3):e002269CrossRefGoogle Scholar
  16. 16.
    Moisseiev E, Abbassi S, Thinda S, Yoon J, Yiu G, Morse LS (2018) Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema. Eur J Ophthalmol 28(1):68–73CrossRefGoogle Scholar
  17. 17.
    Mitchell P, Bandello F, Schmidt-Erfurth U et al (2011) RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 18:615–625CrossRefGoogle Scholar
  18. 18.
    Schmidt-Erfurth U, Lang GE, Holz FG et al (2014) Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 121(5):1045–1053CrossRefGoogle Scholar
  19. 19.
    Brown DM, Schmidt-Erfurth U, Do DV et al (2015) Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 122(10):2044–2052CrossRefGoogle Scholar
  20. 20.
    Campos Polo R, Rubio Sánchez C, García Guisado DM, Díaz Luque MJ (2018) Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice. Clin Ophthalmol 8(12):99–104CrossRefGoogle Scholar
  21. 21.
    Fouda SM, Bahgat AM (2017) Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema. Clin Ophthalmol 11:567–571CrossRefGoogle Scholar
  22. 22.
    Fazel F, Bagheri M, Golabchi K, Jahanbani Ardakani H (2016) Comparison of subthreshold diode laser micropulse therapy versus conventional photocoagulation laser therapy as primary treatment of diabetic macular edema. J Curr Ophthalmol 28(4):206–211CrossRefGoogle Scholar
  23. 23.
    Wells JA, Glassman AR, Ayala AR et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015(13):1193–1203Google Scholar
  24. 24.
    Katz G, Levkovitch-Verbin H, Treister G, Belkin M, Ilany J, Polat U (2010) Mesopic foveal contrast sensitivity is impaired in diabetic patients without retinopathy. Graefes Arch Clin Exp Ophthalmol 248(12):1699–1703CrossRefGoogle Scholar
  25. 25.
    Nixon DR, Flinn NA (2018) Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab. Clin Ophthalmol 22(12):191–197CrossRefGoogle Scholar
  26. 26.
    Mansouri A, Sampat KM, Malik KJ, Steiner JN, Glaser BM (2014) Medscape. Efficacy of subthreshold micropulse laser in the treatment of diabetic macular edema is influenced by pre-treatment central foveal thickness. Eye (Lond) 28(12):1418–1424CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Abeer M. Khattab
    • 1
  • Sherein M. Hagras
    • 1
    • 2
    Email author
  • AhmedHosni AbdElhamid
    • 3
  • Magda A. Torky
    • 1
  • Eman A. Awad
    • 1
  • Ameera G. Abdelhameed
    • 1
  1. 1.Ophthalmology DepartmentMansoura UniversityMansouraEgypt
  2. 2.Ophthalmic Center, Faculty of MedicineMansoura UniversityMansouraEgypt
  3. 3.Ophthalmology DepartmentAin-Shams UniversityCairoEgypt

Personalised recommendations